trending Market Intelligence /marketintelligence/en/news-insights/trending/-ITJl2gmOKCR0jaMUPiClw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Novartis seeks US, EU nods for multiple sclerosis drug

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Novartis seeks US, EU nods for multiple sclerosis drug

Novartis AG is seeking U.S. and EU approval for its drug siponimod to treat an aggressive type of multiple sclerosis, an autoimmune disorder.

The Swiss drugmaker said the U.S. Food and Drug Administration and the European Medicines Agency have accepted the company's drug application for the therapy, which is intended for patients with secondary progressive multiple sclerosis.

MS is characterized by nerve damage in the brain and the spine, leading to loss of physical and cognitive function. The secondary progressive type of the disease is characterized by gradual and irreversible worsening of disability in patients.

The applications are based on data from a phase 3 study of the therapy, called Expand, which showed that siponimod cut the risk of disability progression at three months by 21% in patients with secondary progressive multiple sclerosis compared to placebo.

Siponimod also significantly reduced the annualized rate of relapses in patients with relapsing remitting MS — the most common type of the disease — over six months compared to placebo in a phase 2 study called Bold.

The U.S. and EU drug regulators are expected to decide on siponimod's approval by March 2019 and late 2019, respectively. Novartis said it used a review voucher to speed up the review of siponimod in the U.S.

MS affects about 2.3 million people worldwide.

SNL Image